NovaShunt AG Appoints Key Executives To Its Management Team In Medical Affairs And Commercial Operations
12/2/2009 1:51:41 PM
Zug, Switzerland, December 2, 2009, NovaShunt today announced the appointment of Dr. Pedro Eerdmans as Chief Medical Officer and Dan Rose as Vice President of Commercial Operations and member of the Company’s Board of Directors.
“I’m very delighted to welcome these two highly seasoned professionals to our executive management team which signifies NovaShunt’s commitment to building a strong executive leadership team. Together, Dr. Eerdmans and Mr. Rose bring a wealth of experience and depth of knowledge of clinical research and commercial operations in the medical device field to NovaShunt”, said Noel L. Johnson, CEO and President. “Our innovative technology platform has been proven and we are now moving forward with our final clinical studies for CE marking and preparing for commercialization of our Implantable Automated Fluid Management System for the treatment of refractory ascites.”
As Chief Medical Officer, Pedro Eerdmans will lead NovaShunt’s Clinical Strategy and manage the European clinical team in all markets. Dr. Eerdmans has extensive experience in Clinical Research and Medical Devices. Prior to joining NovaShunt, he was Medical Director at Biosensors responsible for the global clinical program which included more than 12.000 patients post marketing registries and over 1800 patients regulatory studies. Additionally, he spent many years with Medtronic holding management positions in Clinical Research, Ventures and Technology development. Further Pedro Eerdmans has a PhD in Pharmacology and has more than 5 years hospital experience in Orthopedics and Urology. Dr. Eerdmans has authored many peer reviewed papers and holds a patent in the area of wireless pH measurement in the esophagus. “It is a great opportunity to join NovaShunt in this early stage and build the clinical evidence for the AFS system. The AFS system will help a patient population that is in need of a good solution for their refractory ascites. The AFS system can significantly improve quality of life, decrease complications and reduce the burden of refractory ascites patients on the health systems”, said Dr. Eerdmans.
As Vice President of Commercial Operations, Dan Rose will have responsibility for all sales, marketing and business development activities and will be an active member of NovaShunt’s Board of Directors. Mr. Rose spent the past seven years in a number of leadership positions at Medtronic. Most recently, he was Marketing Director for the Coronary and Peripheral Vascular Division in Western Europe. Prior to that, Mr. Rose was Business Manager of the Vascular Division in the Nordic region. He also co-founded a medical device company focused on continuous glucose monitoring technology and spent time working on early stage venture capital opportunities. “I’m very excited about joining the company. NovaShunt’s implantable technology is robust, with major applications in several growing markets. The company’s first product is unique and has the potential to improve clinical outcomes and quality of life for many patients suffering from end-stage liver and heart failure”, said Dan Rose.
About the Automated Fluid Shunt (AFS) System
NovaShunt’s lead product is a battery powered implantable pump system designed to remove excess fluid that collects in the abdominal cavity of patients with advanced liver disease and congestive heart failure. Liver disease is present in 2% of the Western population and is the only major cause of death still increasing every year. Congestive Heart Failure is the fastest growing cardiac disease in the EU and US, also affecting nearly 2% of the population. At present NovaShunt is collecting clinical data to prepare for market launch in Europe in 2010.
NovaShunt is a privately owned Swiss medical device company that aims to become the worldwide leader in design, development, manufacture and marketing of automated implantable pump systems to manage fluid balance within the body. NovaShunt is focused on areas of unmet clinical need where its products can significantly improve clinical outcomes, reduce health care costs and improve patient quality of life.
comments powered by